We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-7.96%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$942M
Cap. Flow
-$762M
Cap. Flow %
-74.8%
Top 10 Hldgs %
36.57%
Holding
87
New
6
Increased
6
Reduced
47
Closed
24

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$15.3M
2
JANX icon
Janux Therapeutics
JANX
+$9.52M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.05M
4
DXCM icon
DexCom
DXCM
+$5.77M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.58M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$48.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$43.4M
3
BSX icon
Boston Scientific
BSX
+$39.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$29.6M
5
ILMN icon
Illumina
ILMN
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$22.7B
$16.1M 1.58%
232,800
-359,200
-61% -$25.9M
AXSM icon
27
Axsome Therapeutics
AXSM
$12.3B
$15.9M 1.56%
188,000
-108,100
-37% -$9.94M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$15.4M 1.51%
176,600
-138,400
-44% -$12.7M
DHR icon
29
Danaher
DHR
$138B
$15.4M 1.51%
67,000
-28,000
-29% -$6.88M
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.65B
$14.8M 1.45%
352,000
-400,000
-53% -$19.8M
ILMN icon
31
Illumina
ILMN
$28.7B
$14.7M 1.44%
109,700
-182,300
-62% -$26M
ABBV icon
32
AbbVie
ABBV
$454B
$14.3M 1.41%
80,700
-19,300
-19% -$3.55M
ARVN icon
33
CALL
Arvinas
ARVN
$530M
$13.4M 1.32%
+700,000
New +$17M
RCKT icon
34
Rocket Pharmaceuticals
RCKT
$355M
$13.2M 1.3%
1,053,300
+304,300
+41% +$4.58M
BMY icon
35
Bristol-Myers Squibb
BMY
$128B
$12.2M 1.19%
215,000
-48,000
-18% -$2.68M
TMDX icon
36
Transmedics
TMDX
$2.57B
$12M 1.18%
192,400
+164,800
+597% +$15.3M
PHAT icon
37
Phathom Pharmaceuticals
PHAT
$953M
$11.3M 1.11%
1,390,100
-414,393
-23% -$5.13M
SGRY icon
38
Surgery Partners
SGRY
$1.98B
$10.9M 1.07%
514,200
-312,800
-38% -$8.21M
ORIC icon
39
Oric Pharmaceuticals
ORIC
$1.24B
$10.2M 1%
1,265,200
-181,919
-13% -$1.67M
NAMS icon
40
NewAmsterdam Pharma
NAMS
$3.53B
$9.1M 0.89%
354,000
-535,700
-60% -$11.4M
INCY icon
41
Incyte
INCY
$23.7B
$8.95M 0.88%
129,600
-178,510
-58% -$12.7M
CATX icon
42
Perspective Therapeutics
CATX
$322M
$8.6M 0.84%
2,694,600
-749,402
-22% -$6.12M
ASND icon
43
Ascendis Pharma A/S
ASND
$16.6B
$8.54M 0.84%
62,000
-57,000
-48% -$7.49M
BHVN icon
44
Biohaven
BHVN
$2.18B
$8.33M 0.82%
222,900
-242,100
-52% -$11.3M
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.1M 0.8%
97,000
-136,000
-58% -$11.2M
IMUX icon
46
Immunic
IMUX
$188M
$7.97M 0.78%
796,640
-29,960
-4% -$377K
CNTX icon
47
Context Therapeutics
CNTX
$57.2M
$7.85M 0.77%
7,477,200
+60,045
+0.8% +$104K
ORKA
48
Oruka Therapeutics
ORKA
$5.44B
$6.83M 0.67%
352,124
-438,802
-55% -$10.7M
REGN icon
49
Regeneron Pharmaceuticals
REGN
$69.9B
$5.98M 0.59%
+8,400
New +$7.05M
BRKR icon
50
Bruker
BRKR
$9.14B
$4.47M 0.44%
+76,300
New +$4.51M
1
2
3 4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2024 Portfolio in Review

As of Q4 2024, Avidity Partners Management held 87 positions worth $1.02B, down 48% from $1.96B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Avidity Partners Management withdrew a net $762M in Q4 2024, closing 24 positions and reducing 47 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $5.98M.

  • Avidity Partners Management's largest Q4 2024 buy was Regeneron Pharmaceuticals: 8,400 shares worth $5.98M.
  • Avidity Partners Management added most to Transmedics in Q4 2024, an estimated $15.3M increase.
  • Avidity Partners Management's biggest Q4 2024 reduction was Natera, cutting an estimated $48.4M.
  • Avidity Partners Management fully exited BioMarin Pharmaceuticals in Q4 2024, selling an estimated $22.5M.
  • Avidity Partners Management's ten largest holdings make up 37% of its $1.02B portfolio in Q4 2024.
  • Avidity Partners Management opened 6 new positions and closed 24 in Q4 2024.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $1.02B.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.